GSK: approval for Benlysta in Japan.
(CercleFinance.com) - GSK (GlaxoSmithKline) announced today that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Benlysta (belimumab) for the treatment of adult patients with systemic lupus erythematosus (SLE) who are inadequate responders to existing therapies.
"SLE is a chronic, incurable, autoimmune disease associated with a range of symptoms that can fluctuate over time, affecting almost any system in the body" the UK pharmaceuticals giant said.
The pharmaceutical laboratory specified that Benlysta's approval in Japan follows the results of two recent pivotal Phase III studies, as well as efficacy and safety data from two previous global Phase III studies.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
"SLE is a chronic, incurable, autoimmune disease associated with a range of symptoms that can fluctuate over time, affecting almost any system in the body" the UK pharmaceuticals giant said.
The pharmaceutical laboratory specified that Benlysta's approval in Japan follows the results of two recent pivotal Phase III studies, as well as efficacy and safety data from two previous global Phase III studies.
Copyright (c) 2017 CercleFinance.com. All rights reserved.